1. Home
  2. IKT vs ULBI Comparison

IKT vs ULBI Comparison

Compare IKT & ULBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKT
  • ULBI
  • Stock Information
  • Founded
  • IKT 2008
  • ULBI 1990
  • Country
  • IKT United States
  • ULBI United States
  • Employees
  • IKT N/A
  • ULBI N/A
  • Industry
  • IKT Biotechnology: Pharmaceutical Preparations
  • ULBI Industrial Machinery/Components
  • Sector
  • IKT Health Care
  • ULBI Miscellaneous
  • Exchange
  • IKT Nasdaq
  • ULBI Nasdaq
  • Market Cap
  • IKT 140.5M
  • ULBI 150.0M
  • IPO Year
  • IKT 2020
  • ULBI 1992
  • Fundamental
  • Price
  • IKT $1.94
  • ULBI $8.65
  • Analyst Decision
  • IKT Buy
  • ULBI Strong Buy
  • Analyst Count
  • IKT 2
  • ULBI 1
  • Target Price
  • IKT $8.00
  • ULBI $14.00
  • AVG Volume (30 Days)
  • IKT 529.3K
  • ULBI 175.0K
  • Earning Date
  • IKT 08-13-2025
  • ULBI 07-24-2025
  • Dividend Yield
  • IKT N/A
  • ULBI N/A
  • EPS Growth
  • IKT N/A
  • ULBI N/A
  • EPS
  • IKT N/A
  • ULBI 0.31
  • Revenue
  • IKT N/A
  • ULBI $173,275,000.00
  • Revenue This Year
  • IKT N/A
  • ULBI $31.30
  • Revenue Next Year
  • IKT N/A
  • ULBI $6.24
  • P/E Ratio
  • IKT N/A
  • ULBI $27.81
  • Revenue Growth
  • IKT N/A
  • ULBI 2.74
  • 52 Week Low
  • IKT $1.12
  • ULBI $4.07
  • 52 Week High
  • IKT $4.20
  • ULBI $12.40
  • Technical
  • Relative Strength Index (RSI)
  • IKT 52.68
  • ULBI 60.98
  • Support Level
  • IKT $1.81
  • ULBI $8.66
  • Resistance Level
  • IKT $2.09
  • ULBI $8.91
  • Average True Range (ATR)
  • IKT 0.14
  • ULBI 0.40
  • MACD
  • IKT 0.02
  • ULBI -0.09
  • Stochastic Oscillator
  • IKT 71.70
  • ULBI 58.62

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

About ULBI Ultralife Corporation

Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.

Share on Social Networks: